• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
3D Bioprinting Market, 2014 - 2030 - Product Image

3D Bioprinting Market, 2014 - 2030

  • ID: 2771982
  • March 2014
  • Region: Global
  • 140 Pages
  • Roots Analysis
3D Bioprinting: The Upcoming Billion Dollar Opportunity

FEATURED COMPANIES

  • 3D Biotek
  • CellASIC
  • Helisys Inc.
  • Mayoclinic
  • Pfizer
  • Seattle Genetics
  • MORE

The 3D printing industry has come a long way over the last many years; the technology has the potential of revolutionising the way things occur currently.

Many industries have already benefitted from multiple advancements in this field, resulting in improved and more efficient processes worldwide. The 3D printing industry has multi-faceted dimensions; the technology has recently been used in varied industries such as automotive, medical, business, industrial equipments, education, architecture, and consumer products. There is a widespread optimism that it is likely to gain prominence in the coming years and have a far reaching impact on our daily lives.

Within healthcare, 3D printed prosthetics and implants have already been in the market for some years. Layerwise from Belgium and Xilloc from Netherlands are the major companies dealing with 3D printed medical and dental implants. Xilloc was in the news recently for creating the first customized 3D-printed lower jaw for an 83-year old patient with a serious jaw infection. Another company, Oxford Performance Materials, from USA, received FDA approval for a 3D printed implant that replaced 75% of a man's skull.

Specifically, READ MORE >

Note: Product cover images may vary from those shown
3D Bioprinting: The Upcoming Billion Dollar Opportunity

FEATURED COMPANIES

  • 3D Biotek
  • CellASIC
  • Helisys Inc.
  • Mayoclinic
  • Pfizer
  • Seattle Genetics
  • MORE

1. PRELUDE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. 3D Printing Technology
3.2.1. What is 3D Printing?
3.2.2. Historical Evolution
3.3. 3D Bioprinting Process And Components
3.4. Entry of 3D Printing into Medical Arena
3.4.1. Key Players
3.4.2. 3D Bioprinting Applications
3.4.2.1. Toxicity Screening / Drug Testing
3.4.2.2. Tissue Engineering
3.4.2.3. Organ Replacement via Organ Printing
3.4.3. Challenges
3.4.3.1. High Initial Cost
3.4.3.2. Regulatory Issues
3.4.3.3. Functional Aspects Not Yet Fully Tested
3.4.3.4. Limited Capability for Complicated Tissues and Organs
3.4.3.5. Hurts Moral and Religious Beliefs

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Limited Professional Bioprinters in Market
4.3. Prices are Largely Prohibitive
4.4. The US is Leading the Efforts; Developing Countries Have Begun to Contribute
4.5. Start-ups Emerging as Key Players
4.6. Bioprinting: Finding its Root in University Research
4.7. Development of Multi-Arm Bioprinters: The Next Generation of Bioprinters

5. PROFILES: COMMERCIAL BIOPRTINERS AND PRODUCTS
5.1. Chapter Overview

5.2. Novogen MMX - Organovo
5.2.1. Overview and Origin
5.2.2. Development of NovoGen MMX
5.2.3. Patents
5.2.4. Awards and Accomplishments
5.2.5. The Bioprinting Process
5.2.6. Bio-ink
5.2.7. Key Features
5.2.8. Applications
5.2.8.1. Microtissues for Drug Discovery and Research
5.2.8.2. Longer Term, Organ Printing for Transplantation
5.2.8.3. Regenerative Medicine
5.2.9. Partnerships and Agreements
5.2.9.1. Pfizer
5.2.9.2. United Therapeutics
5.2.9.3. Autodesk
5.2.9.4. ZenBio
5.2.9.5. OHSU
5.2.9.6. Roche
5.2.9.7. Methuselah Foundation
5.2.9.8. NIH

5.3. 3D-Bioplotter - EnvisionTEC
5.3.1. Overview and Origin
5.3.2. The Bioprinting Process
5.3.3. Applications
5.3.3.1. Provides ‘smart' scaffolds for tissue engineering
5.3.3.2. Cell and Tissue Printing
5.3.3.3. 3D-Anatomical Models for Study
5.3.4. Key Features
5.3.5. Academic Institutions using 3D Bioplotter

5.4. BioFactory - regenHU
5.4.1. Overview and Origin
5.4.2. Features
5.4.3. Research Collaborations
5.4.3.1. ETH, Zurich
5.4.3.2. ZHAW
5.4.4. Applications

5.5. BioAssembly Tool - Sciperio / nScrypt
5.5.1. Overview and Origin
5.5.2. The Bioprinting Process
5.5.3. Key Features
5.5.3.1. SmartPump
5.5.4. Collaborations
5.5.4.1. Cardiovascular Innovation Institute
5.5.5. Awards / Accomplishments
5.5.6. Applications
5.5.6.1. Bioficial Heart
5.5.6.2. Other Tissues

5.6. Microfluidic-based Bioprinting Platform - Aspect Biosystems
5.6.1. Overview and Origin
5.6.2. The Bioprinting Process
5.6.3. Key Features
5.6.4. Building Tissue Constructs For Drug Discovery
5.6.5. Awards
5.6.5.1. MEMSCAP Design Award 2013
5.6.5.2. Federal Support Through IRAP

5.7. Modified Ink-jet Bioprinter - TeVido BioDevices
5.7.1. Overview and Origin
5.7.2. Awards/Accomplishments
5.7.3. The Bioprinting Process
5.7.4. Key Features
5.7.5. Applications
5.7.5.1. Breast Reconstruction
5.7.5.2. Drug Testing
5.7.5.3. Other Reconstructive Tissue Products
5.7.5.4. Treatment for Chronic Wounds
5.7.5.5. Breast Augmentation

5.8. Other Initiatives
5.8.1. SkinPrint
5.8.2. 3DDiscovery - regenHU
5.8.2.1. Key Features
5.8.2.2. Research Collaborations

6. PRODUCT PROFILES: ACADEMIC INSTITUTES
6.1. Chapter Overview

6.2. BioPen - University of Wollongong / St. Vincent Hospital
6.2.1. Overview and Origin
6.2.2. The Bioprinting Process
6.2.3. Advantages of BioPen
6.2.4. Applications

6.3. Modified Ink-jet Bioprinter for Skin Cells - Wake Forest Institute for Regenerative Medicine / Armed Forces Institute For Regenerative Medicine
6.3.1. Overview
6.3.2. The Bioprinting Process
6.3.3. Key Features
6.3.4. Bioprinting Human Skin
6.3.5. Awards / Accomplishments

6.4. Modified Ink-jet Printer for Tissues and Organs - Wake Forest Institute for Regenerative Medicine
6.4.1. Overview
6.4.2. The Bioprinting Process
6.4.3. Applications
6.4.3.1. Tissue Patches
6.4.3.2. Potential to Print Organs
6.4.3.3. Organs on a Chip
6.4.4. Awards/Accomplishments

6.5. Regenovo - Hangzhou Dianzi University, China
6.5.1. Overview
6.5.2. The Bioprinting Process
6.5.3. Key Features
6.5.4. Limitations
6.5.5. Applications

6.6. Valve Based Technology - Heriot-Watt University / Roslin Cellab
6.6.1. Overview and Origin
6.6.2. The Bioprinting Process
6.6.3. Key Features
6.6.4. Applications
6.6.4.1. Drug Testing for Pharmaceutical Research
6.6.4.2. Tissue Regeneration
6.6.4.3. Custom-built Replacement Organs
6.6.5. Awards / Accomplishments
6.6.6. Collaborations
6.6.6.1. Reinnervate Ltd.

7. MARKET FORECAST
7.1. Chapter Overview
7.2. Forecast Methodology
7.3. The 3D Bioprinting Market, 2014 - 2030
7.3.1. Background
7.3.2. Market Forecast: Drug Testing (Base Scenario)
7.3.3. Market Forecast: 3D Bioprinted Skin (Base Scenario)
7.3.4. Market Forecast: 3D Printed Cartilage Replacement (Base Scenario)
7.3.5. Market Forecast: 3D Printed Organ Transplants (Base Scenario)
7.3.6. Overall Market Forecast (Base Scenario)

8. SWOT ANALYSIS
8.1. Chapter Overview
8.2. Strengths
8.2.1. Faster Drug Discovery
8.2.2. A Quality Alternative to Animal Testing
8.3. Weaknesses
8.3.1. High Initial Investment
8.3.2. Integration of Vascular Network
8.4. Opportunities
8.4.1. Low Entry Barriers
8.4.2. Growing Wait List for Organ Transplants – A Huge Unmet Need
8.5. Threats
8.5.1. Regulatory Barrier
8.5.2. Commercial 3D Cell Culture Systems

9. CASE STUDIES
9.1. Organovo Holdings, Inc.
9.2. regenHU

10. INTERVIEW TRANSCRIPTS
10.1. Interview 1: n3D Biosciences (Glauco R. Souza, President and CSO & Hubert Tseng, Senior Research Scientist)
10.2. Interview 2: regenHU (Marc Thurner, CEO)
10.3. Interview 3: Sciperio / nScrypt (Kenneth Church, President and CEO & Xudong Chen, Vice President)
10.4. Interview 4: MicroFab Technologies (Anonymous)
10.5. Interview 5: Digilab (Dr. Igor Zlatkin, Application Scientist & Chirantan Kanani, Technology and Product Development)
10.6. Interview 6: TeVido BioDevices (Laura Bosworth, CEO and Co-Founder)

11. CONCLUSION
11.1. 3D Bioprinting has Emerged Well Since Inception
11.2. Commercial Bioprinters Are Limited; Research Labs and Spin-outs from Academia Continue to Progress
11.3. Organ Supply - Demand Gap: A Major Growth Driver
11.4. Overall a Multi-billion Dollar Opportunity by 2030
11.5. Challenges Exist Before Bioprinting Becomes Mainstream

12. APPENDIX 1: LIST OF COMPANIES AND ORGANISATIONS

13. APPENDIX 2: TABLES

List of Figures

Figure 3.1 The ‘Bioprinting' Process
Figure 4.1 Industry Sponsored Bioprinters: Regional Distribution
Figure 4.2 Industry Sponsored Bioprinters: Distribution by Status
Figure 4.3 University Sponsored Bioprinters: Regional Distribution
Figure 5.1 Bioplotter: Printing Process
Figure 7.1 Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.2 Drug Testing Market, Long Term, Base Scenario (USD MM)
Figure 7.3 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.4 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)
Figure 7.5 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.6 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)
Figure 7.7 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)
Figure 7.8 Overall 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.9 Overall 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)
Figure 10.1 Process of Magnetic Bioprinting
Figure 10.2 3D Cell Bioprinting: Magnetically Beyond Rings and Dots
Figure 10.3 n3D vs. Organovo 3D Bioprinting
Figure 11.1 3D Bioprinting Market, 2018, 2024, 2030 (USD MM)
Figure 11.2 3D Bioprinting: The Driving Forces

List of Tables

Table 3.1 RepRap Project: 3D Printing Machines
Table 3.2 Inputs for 3D Bioprinting
Table 4.1 List of Bioprinters: Industry Sponsored
Table 4.2 Companies Developing Bioprinted Products for Commercial Purposes
Table 4.3 Universities Working in the Area of Bioprinting
Table 5.1 NovoGen MMX: Patent Portfolio
Table 5.2 Materials Used for Scaffolds
Table 5.3 SmartPump - Models and Features
Table 7.1: 3D Bioprinted Applications: Launch Timeline
Table 7.2 3D Bioprinted Skin: Competitive Landscape
Table 8.1 SWOT Analysis
Table 8.2 3D Cell Culture Systems
Table 9.1 3D Liver Assays - Launch Timeline
Table 9.2 Organovo's Plans for Revenue Generation from 3D Bioprinted Liver
Table 9.3 Organovo Revenues – 2011, 2012, and Q1 2013
Table 9.4 regenHU: 3D Bioprinting Product Portfolio
Table 13.1 Industry Sponsored Bioprinters: Regional Distribution
Table 13.2 Industry Sponsored Bioprinters: Distribution by Status
Table 13.3 University Sponsored Bioprinters: Regional Distribution
Table 13.4 Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.5 Drug Testing Market, Long Term, Base Scenario (USD MM)
Table 13.6 Drug Testing Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.7 Drug Testing Market, Long Term, Conservative Scenario (USD MM)
Table 13.8 Drug Testing Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.9 Drug Testing Market, Long Term, Optimistic Scenario (USD MM)
Table 13.10 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.11 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)
Table 13.12 3D Bioprinted Skin Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.13 3D Bioprinted Skin Market, Long Term, Conservative Scenario (USD MM)
Table 13.14 3D Bioprinted Skin Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.15 3D Bioprinted Skin Market, Long Term, Optimistic Scenario (USD MM)
Table 13.16 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.17 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)
Table 13.18 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.19 3D Bioprinted Cartilage Replacement Market, Long Term, Conservative Scenario (USD MM)
Table 13.20 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.21 3D Bioprinted Cartilage Replacement Market, Long Term, Optimistic Scenario (USD MM)
Table 13.22 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)
Table 13.23 3D Bioprinted Organ Transplants, Long Term, Conservative Scenario (USD MM)
Table 13.24 3D Bioprinted Organ Transplants, Long Term, Optimistic Scenario (USD MM)
Table 13.25 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.26 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)
Table 13.27 3D Bioprinted Products Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.28 3D Bioprinted Products Market, Long Term, Conservative Scenario (USD MM)
Table 13.29 3D Bioprinted Products Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.30 3D Bioprinted Products Market, Long Term, Optimistic Scenario (USD MM)

Note: Product cover images may vary from those shown
3D Bioprinting: The Upcoming Billion Dollar Opportunity

FEATURED COMPANIES

  • 3D Biotek
  • CellASIC
  • Helisys Inc.
  • Mayoclinic
  • Pfizer
  • Seattle Genetics
  • MORE

Summary Highlights

- As of today, the industry is primarily focused on research and development; apart from the limited number of industry initiatives, academic groups worldwide are involved in exemplary research in the field of 3D bioprinting.

- A number of start-ups have recently sprung up to develop products based on bioprinting; some of these are spin outs from university research. Examples include TeViDo BioDevices (focused on printing breast tissue), Aspect Biosystems (focused on printing tissue models for toxicity testing) and SkinPrint (focused on developing human skin).

- The market currently has 14 industry sponsored bioprinters, focused on a variety of commercial applications. The widening supply-demand gap for organ transplants is a huge unmet need; the eventual goal of researchers is to be able to produce bioprinted organs for organ transplants.

- As the development progresses, the next generation of bioprinters are likely to offer additional features (e.g. multiple arms) and are likely to be relatively more affordable driving wider adoption.

- It is expected that the market will progress gradually over the coming decade; however, the focus is likely to shift from research to commercialisation by the second half of next decade. At this stage, applications such as drug testing and tissue engineering (skin and cartilage) are likely to be popular.

- By 2030, we predict 3D bioprinting to be a multi-billion dollar industry; early success of bioprinted organ transplants is likely to provide additional boost in subsequent years.

Note: Product cover images may vary from those shown
3D Bioprinting: The Upcoming Billion Dollar Opportunity

- 3D Biotek
- 3D Systems
- Advanced Biomatrix
- Amgen
- Aspect Biosystems
- Asyril
- Autodesk
- Avita Medical
- BD Biosciences
- Bespoke Innovations
- Bio3D Technologies
- CellASIC
- CMC Microsystems
- Cornell
- CP Automation
- Cuspis LLC
- Cyfuse Biomedical
- Cyprotex
- Digilab
- DTM
- EnvisionTEC
- GlycosanBiosystems
- Hangzhou Dianzi University, China
- Helisys Inc.
- Heriot-Watt University
- i.materialise
- ImmunoGen
- InSphero AG
- Invetech
- Invetechon
- Invitrogen
- Kor Ecologic
- Layerwise
- MakerBot Industries
- Mayoclinic
- Methuselah Foundation
- MicroFab Technologies
- Modern Meadows
- n3D Biosciences
- Nano3D Biosciences
- National Institute of Health
- Neatco
- NovoGen
- Objective 3D
- Objet Geometries Ltd
- Organovo Holdings, Inc.
- Oregon Health & Science University
- Oxford Performance Materials
- Pfizer
- QGel
- Rainbow Biosciences
- regenHU
- Reinnervate
- Roche
- Roland DG Corporation
- Roslin Cellab
- Sanofi
- Sciperio / nScrypt
- Scivax
- Seattle Genetics
- SkinPrint
- Solidscape
- Stratasys
- Tengion
- TeVido BioDevices
- The Technology Partnership
- Unique Technology
- United Therapeutics
- Vidi
- Vivos Dental
- Wake Forest Institute for Regenerative Medicine
- Widex
- Xilloc
- Xillocto
- Z Corporation
- ZenBio
- Zurich University of Applied Sciences
- Zyoxel

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos